Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Surgical Wound Infection 5 Neoplasms 4 Colorectal Neoplasms 4 Sepsis 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Leukemia, Myeloid, Acute 2 Febrile Neutropenia 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solitary Pulmonary Nodule 1 Skin Neoplasms 1 Pancreatic Fistula 1 Neutropenia 1 Neoplasms, Plasma Cell 1 Multiple Pulmonary Nodules 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Leukemia 1 Intestinal Neoplasms 1 Inflammation 1 Infections 1 Hematologic Neoplasms 1 Glioblastoma 1 Fever 1 Exanthema 1 Emergencies 1

Interventions

pembrolizumab 300 Nivolumab 273 Ipilimumab 250 aldesleukin 137 Cyclophosphamide 136 Interleukin-2 105 trametinib 82 dabrafenib 76 Temozolomide 75 Dacarbazine 74 Vemurafenib 71 fludarabine 68 fludarabine phosphate 62 Biopsy 49 binimetinib 47 sargramostim 44 Radiosurgery 44 Bevacizumab 43 Paclitaxel 42 encorafenib 40 incomplete Freund's adjuvant 39 atezolizumab 38 Radiotherapy 37 Cisplatin 36 CTLA-4 Antigen 36 Specimen Handling 35 Magnetic Resonance Spectroscopy 35 Carboplatin 35 cobimetinib 34 Introns 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Anti-Bacterial Agents × Clear all

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

14 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡